Ying Luo

Ying Luo is the founder of Shanghai Genomics, Inc. founded in 2001, serving as Chairman since 2021.
Dr. Luo is the founder of GNI Group Ltd. founded in 2005, serving as President, CEO & Representative Director since 2009.
Dr. Luo was the founder of Cullgen, Inc. founded in 2018, served as Chairman, President & Chief Executive Officer from 2018 to 2026.
Current jobs included Chairman & Chief Executive Officer at GNI-EPS Pharmaceuticals, inc.
since 2010; President, Chief Executive Officer & Director at Gyre Therapeutics, Inc. since 2026; Chairman, President & Chief Executive Officer at Cullgen, Inc. (New); Chairman at Continent Pharmaceutical, Inc. since 2011; Chairman & General Manager at Cullgen Shanghai, Inc. since 2018; Chairman at Shanghai GEP Pharmaceuticals, Inc. since 2017; President & Director at GNI Hong Kong Ltd. since 2013; and President & Director at GNI USA, Inc. since 2015.
Former jobs include Chairman at Catalyst Biosciences, Inc.; Chairman at Beijing Continent Pharmaceutical Co., Ltd. from 2011 to 2025; Chairman at Gyre Therapeutics, Inc. from 2023 to 2025; Director at Berkeley Advanced Biomaterials, Inc.; Director-Functional Genomics Division II at Chinese National Genome Center from 2001 to 2011; and Adjunct Professor at Shanghai Jiao Tong University.
Education includes a doctorate from the University of Connecticut Health Center conferred in 1991 and an undergraduate degree from Peking Union Medical College conferred in 1986.